Alexei A. Grom, MD
- Research Director, Division of Rheumatology
- Professor, UC Department of Pediatrics
- alexei.grom@cchmc.org
- Board Certified
About
Biography
My early work with outstanding mentors, who were pediatric rheumatologists, led me to pursue my clinical and research interests. During my fellowship, the unfortunate death of a patient from macrophage activation syndrome (MAS) prompted me to further study this life-threatening complication of systemic juvenile idiopathic arthritis.
Currently, I focus on identifying risk factors and new therapeutic targets in MAS. Our transnational studies have identified interferon gamma (INF), a dimerized soluble cytokine, as a therapeutic target in patients suffering from MAS. This discovery provided the rationale for a new clinical trial that is currently underway.
My research is funded by the National Institutes of Health (NIH) and the Systemic Juvenile Idiopathic Arthritis (SJIA) Foundation. I have also received research grants from Sobi, Novartis and AB2Bio.
MD: Leningrad (St. Petersburg) Pediatric Medical Institute, Russia, 1986.
Residency: Leningrad (St. Petersburg) Medical Institute, Russia, 1988; Children's Hospital Medical Center, Cincinnati, OH, 1998.
Fellowship: Leningrad (St. Petersburg) Pediatric Medical Institute, Russia, 1991; Children's Hospital Medical Center, Cincinnati, OH, 1995.
Certification: Pediatrics, 1999.
Services and Specialties
Rheumatology, Lupus, Rare Lung Diseases
Research Areas
Rheumatology
Additional Languages
French, Russian
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
The 4th NextGen therapies for SJIA and MAS: part 2 phenotypes of refractory SJIA and the landscape for clinical trials in refractory SJIA. Pediatric Rheumatology Online Journal. 2024; 21:87.
Part 5: Allogeneic HSCT in refractory SJIA with lung disease; recent cases from centers in North America & Europe. Pediatric Rheumatology Online Journal. 2024; 21:86.
The 4th NextGen therapies for SJIA and MAS: part 3 clinical trials in refractory SJIA: historic controls as an alternative to a withdrawal design study. Pediatric Rheumatology Online Journal. 2024; 21:150.
Recombinant Interleukin-1 Receptor Antagonist Is an Effective First-Line Treatment Strategy in New-Onset Systemic Juvenile Idiopathic Arthritis, Irrespective of HLA-DRB1 Background and IL1RN Variants. Arthritis and Rheumatology. 2024; 76:119-129.
Population-level single-cell genomics reveals conserved gene programs in systemic juvenile idiopathic arthritis. The Journal of Clinical Investigation. 2023; 133:e166741.
Diagnosis and Management of the Systemic Juvenile Idiopathic Arthritis Patient with Emerging Lung Disease. Pediatric Drugs. 2023; 25:649-658.
The 2022 EULAR/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS). Arthritis and Rheumatology. 2023; 75:1714-1732.
The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). Annals of the Rheumatic Diseases. 2023; 82:1271-1285.
OP0166 LONG-TERM FOLLOW-UP OF PATIENTS ADMINISTERED EMAPALUMAB, AN ANTI–INTERFERON-Γ MONOCLONAL ANTIBODY, TO TREAT MACROPHAGE ACTIVATION SYNDROME (MAS) SECONDARY TO SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA). 2023; 110-111.
Efficacy and safety of emapalumab in macrophage activation syndrome. Annals of the Rheumatic Diseases. 2023; 82:857-865.
From the Blog
Clinical Trial Success Caps Long Journey for HLH Treatment
Alexei A. Grom, MD, Michael B. Jordan, MD3/22/2021
Aggressive Screening Needed to Detect sJIA Lung Complication
Alexei A. Grom, MD, Grant Schulert, MD, PhD10/29/2019
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2024 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey